All About Lercanidipine: Ten Questions and Answers
Abstract
n/a
Keywords:
Dihydropyridine calcium channel blockers, Lercanidipine, kidney function protective effect
Downloads
Download data is not yet available.
References
1 Williams B, Mancia G, Spierin W et al 2018 ESC/ESH Guidelines for the management of arterial hypertension Eur Heart J 2018; 39:3021-3104 https://doi.org/10.1093/eurheartj/ehy439
2 Meredith PA. Lercanidipine: a novel lipophilic dihydropyridine calcium antagonist with long duration of action and high vascular selectivity. Expert Opin Investig Drugs. 1999; 8:1043-1062 https://doi.org/10.1517/13543784.8.7.1043
3 Bang LM, Chapman TM, Goa KL. Lercanidipine: a review of its efficacy in the management of hypertension. Drugs. 2003; 63:2449-2472 https://doi.org/10.2165/00003495-200363220-00013
4 McClellan KJ, Jarvis B. Lercanidipine: a review of its use in hypertension. Drugs. 2000; 60:1123-1140 https://doi.org/10.2165/00003495-200060050-00009
5 Cerbai E, Mugelli U Lercanidipine and T-type calcium current Eur Rev Med Pharmacol Sci 2018; 22:4025-4031
6 Abe M, Okada K, Soma M. T-type Ca channel blockers in patients with chronic kidney disease in clinical practice Curr Hypertens Rev 2013; 9:202-9 https://doi.org/10.2174/1573402110666140131155028
7 Rosenthal T, Rosenmann E, Tomassoni D et al Effect of Lercanidipine on Kidney Microanatomy in Cohen-Rosenthal Diabetic Hypertensive Rats Journal of Cardiovascular Pharmacology 2007; 12:145-152 https://doi.org/10.1177/1074248407300621
8 Robles NR, Fici F, Grassi G Dihydropyridine calcium channel blockers and renal disease Hypertension Res 2017; 40:21-28 https://doi.org/10.1038/hr.2016.85
9 Mancia G, Coca A, Chazova I et al Effects on office and home blood pressure of the lercanidipine-enalapril combination in patients with Stage 2 hypertension: a European randomized,controlled clinical trial Journal of Hypertension 2014, 32:1700-1707 https://doi.org/10.1097/HJH.0000000000000239
10 Burnier M, Gasser UE. Efficacy and tolerability of lercanidipine in patients with hypertension: Results of a phase IV study in general practice. Expert Opin Pharmacother 2007; 8:2215 23 https://doi.org/10.1517/14656566.8.14.2215
11 Grassi G, Robles N R, Seravalle G et al Lercanidipine in the Management of Hypertension: An Update J Pharmacol Pharmacother 2017; 8:155-65 https://doi.org/10.4103/jpp.JPP_34_17
12 Millar-Craig M, Shaffu B, Greenough A Lercanidipine vs lacidipine in isolated systolic hypertension J Hum Hypertens 2003; 17:799-806 https://doi.org/10.1038/sj.jhh.1001614
13 Mackenzie IS, McEniery CM, Dhakam Z, et al. Comparison of the effects of antihypertensive agents on central blood pressure and arterial stiffness in isolated systolic hypertension. Hypertension 2009; 54:409-13 https://doi.org/10.1161/HYPERTENSIONAHA.109.133801
14 Viviani GL. Lercanidipine in type II diabetic patients with mild to moderate arterial hypertension. J Cardiovasc Pharmacol. 2002; 40:133-9 https://doi.org/10.1097/00005344-200207000-00016
15 Barrios V, Escobar C, Navarro A et al Lercanidipine is an effective and well tolerated antihypertensive drug regardless the cardiovascular risk profile: the LAURA Study Int J Clin Pract 2006; 60:1364-70 https://doi.org/10.1111/j.1742-1241.2006.01176.x
16 Makarounas-Kirchmann K, Glover-Koudounas S, Ferrari P. Results of a meta-analysis comparing the tolerability of lercanidipine with the 1st and 2nd generation dihydropyridine calcium channel blockers. Clin Ther. 2009; 31:1652-63 https://doi.org/10.1016/j.clinthera.2009.08.010
17 James IG, Jones A, Davies P. A randomised, double-blind, double-dummy comparison of the efficacy and tolerability of lercanidipine tablets and losartan tablets in patients with mild to moderate essential hypertension. J Hum Hypertens. 2002; 16:605-10 https://doi.org/10.1038/sj.jhh.1001430
18 Aranda P, Aranda FJ, Bianchi JL et al. Therapeutic efficacy and tolerability of lercanidipine versus candesartan, alone or in combination, in mild-moderate essential hypertensives. J Hypertens. 2000; 18-Suppl 2:S152 https://doi.org/10.1097/00004872-200006001-00518
19 Omboni S, Zanchetti A. Antihypertensive efficacy of lercanidipine at 2.5, 5 and 10 mg in mild to moderate essential hypertensives assessed by clinic and ambulatory blood pressure measurements. Multicenter study investigators. J Hypertens 1998; 16:1831-8 https://doi.org/10.1097/00004872-199816120-00017
20 De Ciuceis C, Salvetti M, Rossini C et al Effect of antihypertensive treatment on microvascular structure, central blood pressure and oxidative stress in patients with mild essential hypertension. J Hypertens 2014; 32:565 574 https://doi.org/10.1097/HJH.0000000000000067
21 Poncelet P, Ribstein J, Goullard L, Bassous M, et al. Efficacy and acceptability of lercanidipine are not age dependent in patients with essential hypertension: The AGATE study. Ann Cardiol Angeiol (Paris) 2004; 53:123 30 https://doi.org/10.1016/j.ancard.2004.03.004
22 Panza JA, Casino PR, Kilcoyne CM et al Role of endothelium- derived nitric oxide in the abnormal endothelium-dependent vascular relaxation of patients with essential hypertension. Circulation. 1993; 87:1468-1474 https://doi.org/10.1161/01.CIR.87.5.1468
23Taddei S, Virdis A, Ghiadoni L et al Calcium Antagonist Treatment by Lercanidipine Prevents Hyperpolarization in Essential Hypertension Hypertension 2003; 41:950-955 https://doi.org/10.1161/01.HYP.0000063361.70525.3C
24 Incandela L, Belcaro G M R Cesarone M R et al Oxygen-free radical decrease in hypertensive patients treated with lercanidipine International Angiology 2001;20: 136-140
25 Martinez M LL, Lopes L F, Coelho E B, et al. Lercanidipine reduces matrix metalloproteinase-9 activity in patients with hypertension J Cardiovasc Pharmacol 2006; 47:117-122 https://doi.org/10.1097/01.fjc.0000196241.96759.71
26 Chirinos JA, Segers P, Hughes T et al Large-Artery Stiffness in health and disease JACC State-of-the-Art Review J Am. Coll. Cardiol 2019; 74:1237-1263 https://doi.org/10.1016/j.jacc.2019.07.012
27 Roman MJ, Devereux RB, Kizer JR, et al. Central pressure more strongly relates to vascular disease and outcome than does brachial pressure: the Strong Heart Study. Hypertension. 2007; 50:197-203 https://doi.org/10.1161/HYPERTENSIONAHA.107.089078
28 Weber T, Auer J, O'Rourke MF, et al. Arterial stiffness, wave reflections, and the risk of coronary artery disease. Circulation. 2004; 109(2):184-189 https://doi.org/10.1161/01.CIR.0000105767.94169.E3
29 Grassi G, Seravalle G, Turri C, et al Short versus long term effects of different dihydropyridines on sympathetic and baroreflex function in hypertension. Hypertension 2003; 41:558 62 https://doi.org/10.1161/01.HYP.0000058003.27729.5A
30 Fogari R, Mugellini A, Zoppi A et al Differential effects of lercanidipine and nifedipine GITS on plasma norepinephrine in chronic treatment of hypertension Am J Hypertens 2003; 16:596-9 https://doi.org/10.1016/S0895-7061(03)00901-4
31Robles NR, Fici F, Ari Bakir E,et al Does established vascular kidney disease exist? J Clin Hypertens (Greenwich). 2020; 22:296-298 https://doi.org/10.1111/jch.13818
32 Robles NR, Fici F, Grassi G Dihydropyridine calcium channel blockers and renal Disease Hypertension Res 2017; 40:21-28 https://doi.org/10.1038/hr.2016.85
33 Dalla Vestra M, Pozza G, Mosca A, Grazioli V et al. Effect of lercanidipine compared with ramipril on albumin excretion rate in hypertensive type II diabetic patients with microalbuminuria: DIAL Study (diabete, ipertensione, albuminuria, lercanidipina). Diab Nutr Metab 2004; 17:259-266
34 Robles NR, Ocon J, Gomez CF et al Lercanidipine in patients with chronic renal failure: the ZAFRA study. Ren Fail. 2005; 27:73-80 https://doi.org/10.1081/JDI-42801
35 Peng M, Jiang XJ, Dong H, et al. Can lercanidipine improve renal function in patients with atherosclerotic renal artery stenosis undergoing renal artery intervention? Curr Med Res Opin 2015; 31:177 82 https://doi.org/10.1185/03007995.2014.960071
36 Harrison DG. Cellular and molecular mechanisms of endothelial cell dysfunction. J Clin Invest. 1997; 100:2153-2157 https://doi.org/10.1172/JCI119751
37 Rachmani R, Levi Z, Zadok BS, Ravid M. Losartan and lercanidipine attenuate low density lipoprotein oxidation in patients with hypertension and type 2 diabetes mellitus: A randomized, prospective crossover study. Clin Pharmacol Ther 2002; 72:302-7 https://doi.org/10.1067/mcp.2002.127110
38 Barrios V, Navarro A, Esteras A, et al. Antihypertensive efficacy and tolerability of lercanidipine in daily clinical practice. The ELYPSE study. Eficacia de lercanidipino y su perfil de seguridad. Blood Press 2002; 11:95 100 https://doi.org/10.1080/08037050211265
39 Barrios V, Escobar C, de la Figuera M, et al. High doses of lercanidipine are better tolerated than other dihydropyridines in hypertensive patients with metabolic syndrome: Results from the TOLERANCE study. Int J Clin Pract 2008; 62:723 8 https://doi.org/10.1111/j.1742-1241.2008.01736.x
40 Makani H, Bangalore S, Romero J, et al Peripheral edema associated with calcium channel blockers: Incidence and withdrawal rate - A meta analysis of randomized trials.J Hypertens 2011;29:1270 80 https://doi.org/10.1097/HJH.0b013e3283472643
41 Barrios V, Calderon A, Navarro A et al Lercanidipine effectiveness and tolerability profile is not influenced by overweight or body fat increase. The LERZAMIG study. J Hypertens 2004; 22 Suppl 2:S258 9 https://doi.org/10.1097/00004872-200406002-00908
42 Barrios V, Navarro A, Esteras A, Luque M, et al. Antihypertensive efficacy and tolerability of lercanidipine in daily clinical practice. The ELYPSE study. Eficacia de lercanidipino y su perfil de seguridad. Blood Press 2002; 11:95 100 https://doi.org/10.1080/08037050211265
2 Meredith PA. Lercanidipine: a novel lipophilic dihydropyridine calcium antagonist with long duration of action and high vascular selectivity. Expert Opin Investig Drugs. 1999; 8:1043-1062 https://doi.org/10.1517/13543784.8.7.1043
3 Bang LM, Chapman TM, Goa KL. Lercanidipine: a review of its efficacy in the management of hypertension. Drugs. 2003; 63:2449-2472 https://doi.org/10.2165/00003495-200363220-00013
4 McClellan KJ, Jarvis B. Lercanidipine: a review of its use in hypertension. Drugs. 2000; 60:1123-1140 https://doi.org/10.2165/00003495-200060050-00009
5 Cerbai E, Mugelli U Lercanidipine and T-type calcium current Eur Rev Med Pharmacol Sci 2018; 22:4025-4031
6 Abe M, Okada K, Soma M. T-type Ca channel blockers in patients with chronic kidney disease in clinical practice Curr Hypertens Rev 2013; 9:202-9 https://doi.org/10.2174/1573402110666140131155028
7 Rosenthal T, Rosenmann E, Tomassoni D et al Effect of Lercanidipine on Kidney Microanatomy in Cohen-Rosenthal Diabetic Hypertensive Rats Journal of Cardiovascular Pharmacology 2007; 12:145-152 https://doi.org/10.1177/1074248407300621
8 Robles NR, Fici F, Grassi G Dihydropyridine calcium channel blockers and renal disease Hypertension Res 2017; 40:21-28 https://doi.org/10.1038/hr.2016.85
9 Mancia G, Coca A, Chazova I et al Effects on office and home blood pressure of the lercanidipine-enalapril combination in patients with Stage 2 hypertension: a European randomized,controlled clinical trial Journal of Hypertension 2014, 32:1700-1707 https://doi.org/10.1097/HJH.0000000000000239
10 Burnier M, Gasser UE. Efficacy and tolerability of lercanidipine in patients with hypertension: Results of a phase IV study in general practice. Expert Opin Pharmacother 2007; 8:2215 23 https://doi.org/10.1517/14656566.8.14.2215
11 Grassi G, Robles N R, Seravalle G et al Lercanidipine in the Management of Hypertension: An Update J Pharmacol Pharmacother 2017; 8:155-65 https://doi.org/10.4103/jpp.JPP_34_17
12 Millar-Craig M, Shaffu B, Greenough A Lercanidipine vs lacidipine in isolated systolic hypertension J Hum Hypertens 2003; 17:799-806 https://doi.org/10.1038/sj.jhh.1001614
13 Mackenzie IS, McEniery CM, Dhakam Z, et al. Comparison of the effects of antihypertensive agents on central blood pressure and arterial stiffness in isolated systolic hypertension. Hypertension 2009; 54:409-13 https://doi.org/10.1161/HYPERTENSIONAHA.109.133801
14 Viviani GL. Lercanidipine in type II diabetic patients with mild to moderate arterial hypertension. J Cardiovasc Pharmacol. 2002; 40:133-9 https://doi.org/10.1097/00005344-200207000-00016
15 Barrios V, Escobar C, Navarro A et al Lercanidipine is an effective and well tolerated antihypertensive drug regardless the cardiovascular risk profile: the LAURA Study Int J Clin Pract 2006; 60:1364-70 https://doi.org/10.1111/j.1742-1241.2006.01176.x
16 Makarounas-Kirchmann K, Glover-Koudounas S, Ferrari P. Results of a meta-analysis comparing the tolerability of lercanidipine with the 1st and 2nd generation dihydropyridine calcium channel blockers. Clin Ther. 2009; 31:1652-63 https://doi.org/10.1016/j.clinthera.2009.08.010
17 James IG, Jones A, Davies P. A randomised, double-blind, double-dummy comparison of the efficacy and tolerability of lercanidipine tablets and losartan tablets in patients with mild to moderate essential hypertension. J Hum Hypertens. 2002; 16:605-10 https://doi.org/10.1038/sj.jhh.1001430
18 Aranda P, Aranda FJ, Bianchi JL et al. Therapeutic efficacy and tolerability of lercanidipine versus candesartan, alone or in combination, in mild-moderate essential hypertensives. J Hypertens. 2000; 18-Suppl 2:S152 https://doi.org/10.1097/00004872-200006001-00518
19 Omboni S, Zanchetti A. Antihypertensive efficacy of lercanidipine at 2.5, 5 and 10 mg in mild to moderate essential hypertensives assessed by clinic and ambulatory blood pressure measurements. Multicenter study investigators. J Hypertens 1998; 16:1831-8 https://doi.org/10.1097/00004872-199816120-00017
20 De Ciuceis C, Salvetti M, Rossini C et al Effect of antihypertensive treatment on microvascular structure, central blood pressure and oxidative stress in patients with mild essential hypertension. J Hypertens 2014; 32:565 574 https://doi.org/10.1097/HJH.0000000000000067
21 Poncelet P, Ribstein J, Goullard L, Bassous M, et al. Efficacy and acceptability of lercanidipine are not age dependent in patients with essential hypertension: The AGATE study. Ann Cardiol Angeiol (Paris) 2004; 53:123 30 https://doi.org/10.1016/j.ancard.2004.03.004
22 Panza JA, Casino PR, Kilcoyne CM et al Role of endothelium- derived nitric oxide in the abnormal endothelium-dependent vascular relaxation of patients with essential hypertension. Circulation. 1993; 87:1468-1474 https://doi.org/10.1161/01.CIR.87.5.1468
23Taddei S, Virdis A, Ghiadoni L et al Calcium Antagonist Treatment by Lercanidipine Prevents Hyperpolarization in Essential Hypertension Hypertension 2003; 41:950-955 https://doi.org/10.1161/01.HYP.0000063361.70525.3C
24 Incandela L, Belcaro G M R Cesarone M R et al Oxygen-free radical decrease in hypertensive patients treated with lercanidipine International Angiology 2001;20: 136-140
25 Martinez M LL, Lopes L F, Coelho E B, et al. Lercanidipine reduces matrix metalloproteinase-9 activity in patients with hypertension J Cardiovasc Pharmacol 2006; 47:117-122 https://doi.org/10.1097/01.fjc.0000196241.96759.71
26 Chirinos JA, Segers P, Hughes T et al Large-Artery Stiffness in health and disease JACC State-of-the-Art Review J Am. Coll. Cardiol 2019; 74:1237-1263 https://doi.org/10.1016/j.jacc.2019.07.012
27 Roman MJ, Devereux RB, Kizer JR, et al. Central pressure more strongly relates to vascular disease and outcome than does brachial pressure: the Strong Heart Study. Hypertension. 2007; 50:197-203 https://doi.org/10.1161/HYPERTENSIONAHA.107.089078
28 Weber T, Auer J, O'Rourke MF, et al. Arterial stiffness, wave reflections, and the risk of coronary artery disease. Circulation. 2004; 109(2):184-189 https://doi.org/10.1161/01.CIR.0000105767.94169.E3
29 Grassi G, Seravalle G, Turri C, et al Short versus long term effects of different dihydropyridines on sympathetic and baroreflex function in hypertension. Hypertension 2003; 41:558 62 https://doi.org/10.1161/01.HYP.0000058003.27729.5A
30 Fogari R, Mugellini A, Zoppi A et al Differential effects of lercanidipine and nifedipine GITS on plasma norepinephrine in chronic treatment of hypertension Am J Hypertens 2003; 16:596-9 https://doi.org/10.1016/S0895-7061(03)00901-4
31Robles NR, Fici F, Ari Bakir E,et al Does established vascular kidney disease exist? J Clin Hypertens (Greenwich). 2020; 22:296-298 https://doi.org/10.1111/jch.13818
32 Robles NR, Fici F, Grassi G Dihydropyridine calcium channel blockers and renal Disease Hypertension Res 2017; 40:21-28 https://doi.org/10.1038/hr.2016.85
33 Dalla Vestra M, Pozza G, Mosca A, Grazioli V et al. Effect of lercanidipine compared with ramipril on albumin excretion rate in hypertensive type II diabetic patients with microalbuminuria: DIAL Study (diabete, ipertensione, albuminuria, lercanidipina). Diab Nutr Metab 2004; 17:259-266
34 Robles NR, Ocon J, Gomez CF et al Lercanidipine in patients with chronic renal failure: the ZAFRA study. Ren Fail. 2005; 27:73-80 https://doi.org/10.1081/JDI-42801
35 Peng M, Jiang XJ, Dong H, et al. Can lercanidipine improve renal function in patients with atherosclerotic renal artery stenosis undergoing renal artery intervention? Curr Med Res Opin 2015; 31:177 82 https://doi.org/10.1185/03007995.2014.960071
36 Harrison DG. Cellular and molecular mechanisms of endothelial cell dysfunction. J Clin Invest. 1997; 100:2153-2157 https://doi.org/10.1172/JCI119751
37 Rachmani R, Levi Z, Zadok BS, Ravid M. Losartan and lercanidipine attenuate low density lipoprotein oxidation in patients with hypertension and type 2 diabetes mellitus: A randomized, prospective crossover study. Clin Pharmacol Ther 2002; 72:302-7 https://doi.org/10.1067/mcp.2002.127110
38 Barrios V, Navarro A, Esteras A, et al. Antihypertensive efficacy and tolerability of lercanidipine in daily clinical practice. The ELYPSE study. Eficacia de lercanidipino y su perfil de seguridad. Blood Press 2002; 11:95 100 https://doi.org/10.1080/08037050211265
39 Barrios V, Escobar C, de la Figuera M, et al. High doses of lercanidipine are better tolerated than other dihydropyridines in hypertensive patients with metabolic syndrome: Results from the TOLERANCE study. Int J Clin Pract 2008; 62:723 8 https://doi.org/10.1111/j.1742-1241.2008.01736.x
40 Makani H, Bangalore S, Romero J, et al Peripheral edema associated with calcium channel blockers: Incidence and withdrawal rate - A meta analysis of randomized trials.J Hypertens 2011;29:1270 80 https://doi.org/10.1097/HJH.0b013e3283472643
41 Barrios V, Calderon A, Navarro A et al Lercanidipine effectiveness and tolerability profile is not influenced by overweight or body fat increase. The LERZAMIG study. J Hypertens 2004; 22 Suppl 2:S258 9 https://doi.org/10.1097/00004872-200406002-00908
42 Barrios V, Navarro A, Esteras A, Luque M, et al. Antihypertensive efficacy and tolerability of lercanidipine in daily clinical practice. The ELYPSE study. Eficacia de lercanidipino y su perfil de seguridad. Blood Press 2002; 11:95 100 https://doi.org/10.1080/08037050211265
Statistics
30 Views | 3 Downloads
How to Cite
1.
Fici F, Faikoglu G, Grassi G, Robles NR, Faikoglu KS. All About Lercanidipine: Ten Questions and Answers. JDDT [Internet]. 15Mar.2023 [cited 22Mar.2023];13(3):P1-P3. Available from: https://jddtonline.info/index.php/jddt/article/view/5769
Section
Letter to Editor
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Authors who publish with this journal agree to the following terms:
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0). that allows others to share the work with an acknowledgment of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).
.